iTeos Therapeutics, Inc.
ITOSHealthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | |
|---|---|---|---|---|---|---|
| Revenue | $35.0M | $12.6M | $267.6M | $344.8M | — | — |
| Operating income | −$159.5M | −$151.1M | $126.3M | $244.9M | −$45.2M | −$28.0M |
| Net income | −$134.4M | −$112.6M | $96.7M | $214.5M | −$38.0M | −$22.5M |
| Total assets | $687.0M | $667.6M | $755.0M | $884.7M | $344.6M | $30.7M |
| Total liabilities | $96.7M | $92.4M | $91.7M | $331.9M | $21.4M | $15.1M |
| Equity | $590.3M | $575.2M | $663.3M | $552.8M | $323.2M | −$36.1M |
| EPS (diluted) | $-3.32 | $-3.15 | $2.56 | $5.68 | $-2.88 | — |
| Shares out. | 35.8M | 35.7M | 35.5M | 35.1M | 35.0M | 256,548 |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2024- Operating margin
- −455.8%
- Net margin
- −384.0%
- Return on equity
- −22.8%
- Return on assets
- −19.6%
- Return on capital (ROCE)
- −24.7%
- Liabilities / assets
- 14.1%
- Debt / equity
- 0.16×
- Book value / share
- $16.47
- Revenue growth (YoY)
- 177.9%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2024- Altman Z″ (distress)
- 9.28safe
- Accruals / assets
- −5.3%clean
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 3 warning● 4 good- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1/2Active Not Recruitingreadout ~2024-07Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
- Phase 2Active Not Recruitingreadout ~2025-06-13Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer
- Phase 1Active Not Recruitingreadout ~2025-12A First-in-Human Study of EOS301984 as Monotherapy or Combination Therapy in Adult Participants With Advanced Solid Tumors
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Ridgeback Capital Investments L.P.Passive (13G)Nov 14, 2025
- Tang Capital Management LlcActivist (13D)Sep 3, 2025
- Biotechnology Value Fund L PPassive (13G)Aug 14, 2025
- Ra Capital Management, L.P.Activist (13D)May 19, 2025
- Ecor1 Capital, LlcActivist (13D)May 16, 2025
- Mpm Bioventures 2014, L.P.Activist (13D)May 15, 2025
- Blackrock, Inc.Passive (13G)Apr 23, 2025
- Blackrock Portfolio Management LlcPassive (13G)Apr 15, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| Aug 29, 2025 | 896,750 | 1.0 | -56.5% |
| Aug 15, 2025 | 2.1M | 1.9 | -30.5% |
| Jul 31, 2025 | 3.0M | 1.6 | -3.3% |
| Jul 15, 2025 | 3.1M | 4.4 | +8.4% |
| Jun 30, 2025 | 2.8M | 3.1 | +4.9% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsAug 29, 2025
- Entered a material agreement · Director / officer change · Regulation FD disclosure · Other material eventJul 21, 2025
- Shareholder voteJun 17, 2025
- Director / officer changeJun 5, 2025
- Costs from exit or disposal · Director / officer change · Regulation FD disclosureMay 28, 2025
- Terminated a material agreement · Regulation FD disclosureMay 13, 2025
- Regulation FD disclosureJan 13, 2025
- Director / officer changeNov 4, 2024
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.